Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Fondazione Ricerca Traslazionale

ClinicalTrials.gov lists Fondazione Ricerca Traslazionale as lead sponsor of 15 trials. It has 14 active development programs and 13 approved assets.

IT Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

3 0 2014 2026

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.

This page covers Fondazione Ricerca Traslazionale: 15 lead-sponsored trials and 1 legal-entity registration.

Get the Fondazione Ricerca Traslazionale report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (3)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Carcinoma, Non-Small-Cell Lung 8
Lung Neoplasms 8
Neoplasm Metastasis 1

Trials by start year as sponsor or collaborator (9)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2025 3
2022 1
2021 2
2020 2
2019 1
2018 1
2017 3
2015 1
2014 1

Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (14)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Tedopi Lung Neoplasms Phase 2 1
surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines Carcinoma, Non-Small-Cell Lung Phase 2 1
surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines Lung Neoplasms Phase 2 1
Chemoradiotherapy Carcinoma, Non-Small-Cell Lung Phase 2 1
Tedopi Carcinoma, Non-Small-Cell Lung Phase 2 1

Showing 5 of 14 active programs.

Start your 14-day trial Email me all 14 active programs as a PDF

Approved assets (13)

Shown in this order: max phase first.

Approved assets
Drug Trials
Tislelizumab 1
CABOZANTINIB 1
DURVALUMAB 1
BEVACIZUMAB 1
Amivantamab 1

Showing 5 of 13 approved assets.

Start your 14-day trial Email me all 13 approved assets as a PDF

Journals published in (26)

Shown in this order: most published in first.

Journals published in
Journal Publications
The New England journal of medicine 5
Clinical lung cancer 3
Journal of clinical pharmacology 3
Annual review of immunology 2
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2

Showing 5 of 26 journals.

Start your 14-day trial Email me all 26 journals as a PDF

Organization relationships (1)

Organization relationships
Related organization Relationship Evidence
Clinical Research Technology S.r.l. Co sponsors trial with 1

Latest dated events (15)

Shown in this order: newest first.

Latest dated events
Date Event Source
2025-12-02 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-04-17 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-03-27 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2022-05-02 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2021-10-12 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Showing 5 of 15 events.

Start your 14-day trial Email me all 15 events as a PDF

Biomarker capability evidence (120)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ALK Trial sponsor Named in trial inclusion criteria
ALK Trial sponsor Named in trial inclusion criteria
ALK Trial sponsor Named in trial inclusion criteria
ALK Trial sponsor Named in trial inclusion criteria
ALK Trial sponsor Named in trial inclusion criteria

Showing 5 of 120 evidence rows.

Start your 14-day trial Email me the first 50 evidence rows as a PDF

Biomarkers this organization publishes on (9)

Shown in this order: most publications first.

Biomarkers this organization publishes on
Biomarker Publications
ALCAM 1
ALDH1A1 1
ALK 1
EGF 1
EGFR 1

Showing 5 of 9 biomarkers.

Start your 14-day trial Email me all 9 biomarkers as a PDF

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.